{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:02:05Z","timestamp":1794013325396,"version":"4.8.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01286-w","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:02:19Z","timestamp":1750208539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group"],"prefix":"10.1038","volume":"15","author":[{"given":"Xinyan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica F.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3857-9519","authenticated-orcid":false,"given":"Celeste C.","family":"Eno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"Miron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Quintero-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2569-3511","authenticated-orcid":false,"given":"Virginia C.","family":"Thurston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daynna J.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5229-4897","authenticated-orcid":false,"given":"Linda B.","family":"Baughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"1286_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15:409\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"1286_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ijlh.12882","volume":"41","author":"D Saxe","year":"2019","unstructured":"Saxe D, Seo EJ, Bergeron MB, Han JY. Recent advances in cytogenetic characterization of multiple myeloma. Int J Lab Hematol. 2019;41:5\u201314.","journal-title":"Int J Lab Hematol"},{"key":"1286_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00348-5","volume":"10","author":"N Abdallah","year":"2020","unstructured":"Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, et al. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J. 2020;10:82.","journal-title":"Blood Cancer J"},{"key":"1286_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.92","volume":"5","author":"AM Rajan","year":"2015","unstructured":"Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015;5:e365.","journal-title":"Blood Cancer J"},{"key":"1286_CR5","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025; In Press. https:\/\/healthtree.org\/myeloma\/community\/articles\/ims-2024-high-risk-mm-report."},{"key":"1286_CR6","unstructured":"Network NCC. Multiple Myeloma (Version 4.2024). [cited September 11, 2024]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf."},{"key":"1286_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","volume":"82","author":"A Dispenzieri","year":"2007","unstructured":"Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323\u201341.","journal-title":"Mayo Clin Proc"},{"key":"1286_CR8","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"1286_CR9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360\u201376.","journal-title":"Mayo Clin Proc"},{"key":"1286_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cancergen.2018.07.002","volume":"228-229","author":"TJ Pugh","year":"2018","unstructured":"Pugh TJ, Fink JM, Lu X, Mathew S, Murata-Collins J, Willem P, et al. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders. Cancer Genet. 2018;228-229:184\u201396.","journal-title":"Cancer Genet"},{"key":"1286_CR11","doi-asserted-by":"publisher","first-page":"e1169","DOI":"10.1200\/JOP.19.00639","volume":"16","author":"Y Yu","year":"2020","unstructured":"Yu Y, Brown Wade N, Hwang AE, Nooka AK, Fiala MA, Mohrbacher A, et al. Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. JCO Oncol Pr. 2020;16:e1169\u201380.","journal-title":"JCO Oncol Pr"},{"key":"1286_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00985-0","volume":"14","author":"K Neupane","year":"2024","unstructured":"Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, et al. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J. 2024;14:20.","journal-title":"Blood Cancer J"},{"key":"1286_CR13","doi-asserted-by":"publisher","first-page":"e710","DOI":"10.1016\/j.clml.2021.05.001","volume":"21","author":"A Ravindran","year":"2021","unstructured":"Ravindran A, Greipp PT, Wongchaowart N, Smadbeck JB, Peterson JF, Ketterling RP, et al. Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. Clin Lymphoma Myeloma Leuk. 2021;21:e710\u20133.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1286_CR14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/sj.leu.2401041","volume":"12","author":"NV Smadja","year":"1998","unstructured":"Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998;12:960\u20139.","journal-title":"Leukemia"},{"key":"1286_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/sj.leu.2402797","volume":"17","author":"CS Debes-Marun","year":"2003","unstructured":"Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003;17:427\u201336.","journal-title":"Leukemia"},{"key":"1286_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0285-6","volume":"10","author":"G Barila","year":"2020","unstructured":"Barila G, Bonaldi L, Grassi A, Martines A, Lico A, Macri N, et al. Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis. Blood Cancer J. 2020;10:18.","journal-title":"Blood Cancer J"},{"key":"1286_CR17","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1080\/10428190600822128","volume":"47","author":"JJ Keats","year":"2006","unstructured":"Keats JJ, Reiman T, Belch AR, Pilarski LM. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma. 2006;47:2289\u20132300.","journal-title":"Leuk Lymphoma"},{"key":"1286_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00933-4","volume":"13","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Perrot A, Cazaubiel T, Leleu X, Montes L, Jacquet C, et al. Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions. Blood Cancer J. 2023;13:160.","journal-title":"Blood Cancer J"},{"key":"1286_CR19","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3324\/haematol.2009.016329","volume":"95","author":"FM Ross","year":"2010","unstructured":"Ross FM, Chiecchio L, Dagrada G, Protheroe RK, Stockley DM, Harrison CJ, et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica. 2010;95:1221\u20135.","journal-title":"Haematologica"},{"key":"1286_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0307-4","volume":"10","author":"R Mina","year":"2020","unstructured":"Mina R, Joseph NS, Gay F, Kastritis E, Petrucci MT, Kaufman JL, et al. Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer J. 2020;10:40.","journal-title":"Blood Cancer J"},{"key":"1286_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997.","journal-title":"Nat Commun"},{"key":"1286_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15740-9","volume":"11","author":"EH Rustad","year":"2020","unstructured":"Rustad EH, Yellapantula V, Leongamornlert D, Bolli N, Ledergor G, Nadeu F, et al. Timing the initiation of multiple myeloma. Nat Commun. 2020;11:1917.","journal-title":"Nat Commun"},{"key":"1286_CR23","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2017.345","volume":"32","author":"F Maura","year":"2018","unstructured":"Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2018;32:1044\u20138.","journal-title":"Leukemia"},{"key":"1286_CR24","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1200\/JCO.20.00461","volume":"38","author":"MK Samur","year":"2020","unstructured":"Samur MK, Aktas Samur A, Fulciniti M, Szalat R, Han T, Shammas M, et al. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020;38:3107\u201318.","journal-title":"J Clin Oncol"},{"key":"1286_CR25","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","volume":"99","author":"R Fonseca","year":"2002","unstructured":"Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735\u201341.","journal-title":"Blood"},{"key":"1286_CR26","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","volume":"100","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579\u201383.","journal-title":"Blood"},{"key":"1286_CR27","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1182\/blood-2018-09-876433","volume":"132","author":"A Cleynen","year":"2018","unstructured":"Cleynen A, Samur M, Perrot A, Buisson L, Maheo S, Fulciniti M, et al. Variable BCL2\/BCL2L1 ratio in multiple myeloma with t(11;14). Blood. 2018;132:2778\u201380.","journal-title":"Blood"},{"key":"1286_CR28","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","volume":"32","author":"C Touzeau","year":"2018","unstructured":"Touzeau C, Maciag P, Amiot M, Moreau P. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia. 2018;32:1899\u2013907.","journal-title":"Leukemia"},{"key":"1286_CR29","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401\u20139.","journal-title":"Blood"},{"key":"1286_CR30","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1182\/blood-2022-170749","volume":"140","author":"C Bonolo De Campos","year":"2022","unstructured":"Bonolo De Campos C, Smadbeck JB, Arribas M, Sharma N, Ahmann GJ, Kumar SK, et al. A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma. Blood. 2022;140:7180\u20131.","journal-title":"Blood"},{"key":"1286_CR31","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/modpathol.2017.63","volume":"30","author":"S Hao","year":"2017","unstructured":"Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, et al. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol. 2017;30:1378\u201386.","journal-title":"Mod Pathol"},{"key":"1286_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1096852","volume":"12","author":"C Marcon","year":"2022","unstructured":"Marcon C, Simeon V, Deias P, Facchin G, Corso A, Derudas D, et al. Experts\u2019 consensus on the definition and management of high risk multiple myeloma. Front Oncol. 2022;12:1096852.","journal-title":"Front Oncol"},{"key":"1286_CR33","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","volume":"102","author":"S Thanendrarajan","year":"2017","unstructured":"Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017;102:e364\u201367.","journal-title":"Haematologica"},{"key":"1286_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00919-2","volume":"13","author":"E Liu","year":"2023","unstructured":"Liu E, Sudha P, Becker N, Jaouadi O, Suvannasankha A, Lee K, et al. Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma. Blood Cancer J. 2023;13:144.","journal-title":"Blood Cancer J"},{"key":"1286_CR35","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood.2022017863","volume":"141","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, et al. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood. 2023;141:1308\u201315.","journal-title":"Blood"},{"key":"1286_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11684-019-0712-x","volume":"14","author":"H Wang","year":"2020","unstructured":"Wang H, Meng H, Wang J, Lou Y, Zhou Y, Lin P, et al. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China. Front Med. 2020;14:327\u201334.","journal-title":"Front Med"},{"key":"1286_CR37","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","volume":"35","author":"J Croft","year":"2021","unstructured":"Croft J, Ellis S, Sherborne AL, Sharp K, Price A, Jenner MW, et al. Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia. 2021;35:2043\u201353.","journal-title":"Leukemia"},{"key":"1286_CR38","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","volume":"116","author":"BA Walker","year":"2010","unstructured":"Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116:e56\u201365.","journal-title":"Blood"},{"key":"1286_CR39","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"FM Ross","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, O\u2019Connor S, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97:1272\u20137.","journal-title":"Haematologica"},{"key":"1286_CR40","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","volume":"4","author":"N Abdallah","year":"2020","unstructured":"Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4:3509\u201319.","journal-title":"Blood Adv"},{"key":"1286_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00474-8","volume":"11","author":"TM Schmidt","year":"2021","unstructured":"Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021;11:83.","journal-title":"Blood Cancer J"},{"key":"1286_CR42","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","volume":"102","author":"R Fonseca","year":"2003","unstructured":"Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102:2562\u20137.","journal-title":"Blood"},{"key":"1286_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2023.100816","volume":"1","author":"A Koleilat","year":"2023","unstructured":"Koleilat A, Tang H, Sharma N, Yan H, Tian S, Smadbeck J, et al. Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasm. Genet Med Open. 2023;1:100816.","journal-title":"Genet Med Open"},{"key":"1286_CR44","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ajh.25391","volume":"94","author":"S Sidana","year":"2019","unstructured":"Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, et al. Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. Am J Hematol. 2019;94:424\u201330.","journal-title":"Am J Hematol"},{"key":"1286_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0182-z","volume":"9","author":"JF Peterson","year":"2019","unstructured":"Peterson JF, Rowsey RA, Marcou CA, Pearce KE, Williamson CM, Frederick LA, et al. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer J. 2019;9:20.","journal-title":"Blood Cancer J"},{"key":"1286_CR46","doi-asserted-by":"publisher","first-page":"732","DOI":"10.18632\/oncotarget.26589","volume":"10","author":"C Ashby","year":"2019","unstructured":"Ashby C, Tytarenko RG, Wang Y, Weinhold N, Johnson SK, Bauer M, et al. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget. 2019;10:732\u20137.","journal-title":"Oncotarget"},{"key":"1286_CR47","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/gcc.22165","volume":"53","author":"E Tian","year":"2014","unstructured":"Tian E, Sawyer JR, Heuck CJ, Zhang Q, van Rhee F, Barlogie B, et al. In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes. Genes Chromosomes Cancer. 2014;53:549\u201357.","journal-title":"Genes Chromosomes Cancer"},{"key":"1286_CR48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel PL, Kuehl WM, Zhan FH, Sawyer J, Barlogie B, Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296\u2013303.","journal-title":"Blood"},{"key":"1286_CR49","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020\u20138.","journal-title":"Blood"},{"key":"1286_CR50","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56:1878\u201389.","journal-title":"Nat Genet"},{"key":"1286_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1611375","volume":"29","author":"A Cegledi","year":"2023","unstructured":"Cegledi A, Csukly Z, Fekete M, Kozma A, Szemlaky Z, Andrikovics H, et al. Effective venetoclax-based treatment in relapsed\/refractory multiple myeloma patients with translocation t(6;14). Pathol Oncol Res. 2023;29:1611375.","journal-title":"Pathol Oncol Res"},{"key":"1286_CR52","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3324\/haematol.2019.217927","volume":"105","author":"A Mikulasova","year":"2020","unstructured":"Mikulasova A, Ashby C, Tytarenko RG, Qu P, Rosenthal A, Dent JA, et al. Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma. Haematologica. 2020;105:1055\u201366.","journal-title":"Haematologica"},{"key":"1286_CR53","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1158\/1078-0432.CCR-21-0005","volume":"27","author":"N Sharma","year":"2021","unstructured":"Sharma N, Smadbeck JB, Abdallah N, Zepeda-Mendoza C, Binder M, Pearce KE, et al. The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma. Clin Cancer Res. 2021;27:5430\u20139.","journal-title":"Clin Cancer Res"},{"key":"1286_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.13","volume":"4","author":"BA Walker","year":"2014","unstructured":"Walker BA, Wardell CP, Brioli A, Boyle E, Kaiser MF, Begum DB, et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J. 2014;4:e191.","journal-title":"Blood Cancer J"},{"key":"1286_CR55","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","volume":"34","author":"K Misund","year":"2020","unstructured":"Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, et al. MYC dysregulation in the progression of multiple myeloma. Leukemia. 2020;34:322\u20136.","journal-title":"Leukemia"},{"key":"1286_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20524-2","volume":"12","author":"EM Boyle","year":"2021","unstructured":"Boyle EM, Deshpande S, Tytarenko R, Ashby C, Wang Y, Bauer MA, et al. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun. 2021;12:293.","journal-title":"Nat Commun"},{"key":"1286_CR57","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/leu.2014.70","volume":"28","author":"M Affer","year":"2014","unstructured":"Affer M, Chesi M, Chen WG, Keats JJ, Demchenko YN, Roschke AV, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014;28:1725\u201335.","journal-title":"Leukemia"},{"key":"1286_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09555-6","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick BG, Neri P, Bahlis NJ, Nooka AK, Dhodapkar MV, Jaye DL, et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat Commun. 2019;10:1911.","journal-title":"Nat Commun"},{"key":"1286_CR59","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/leu.2009.174","volume":"23","author":"R Fonseca","year":"2009","unstructured":"Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210\u201321.","journal-title":"Leukemia"},{"key":"1286_CR60","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","volume":"99","author":"H Avet-Loiseau","year":"2002","unstructured":"Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99:2185\u201391.","journal-title":"Blood"},{"key":"1286_CR61","first-page":"715","volume":"62","author":"R Fonseca","year":"2002","unstructured":"Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res. 2002;62:715\u201320.","journal-title":"Cancer Res"},{"key":"1286_CR62","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/sj.leu.2404304","volume":"20","author":"L Chiecchio","year":"2006","unstructured":"Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20:1610\u20137.","journal-title":"Leukemia"},{"key":"1286_CR63","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","volume":"109","author":"H Avet-Loiseau","year":"2007","unstructured":"Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489\u201395.","journal-title":"Blood"},{"key":"1286_CR64","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/leu.2013.86","volume":"27","author":"SV Rajkumar","year":"2013","unstructured":"Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27:1738\u201344.","journal-title":"Leukemia"},{"key":"1286_CR65","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/ejh.13905","volume":"110","author":"M Locher","year":"2023","unstructured":"Locher M, Jukic E, Vogi V, Keller MA, Kroll T, Schwendinger S, et al. Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma. Eur J Haematol. 2023;110:296\u2013304.","journal-title":"Eur J Haematol"},{"key":"1286_CR66","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1002\/ajh.25420","volume":"94","author":"S Sidana","year":"2019","unstructured":"Sidana S, Jevremovic D, Ketterling RP, Tandon N, Greipp PT, Baughn LB, et al. Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. Am J Hematol. 2019;94:E117\u2013E120.","journal-title":"Am J Hematol"},{"key":"1286_CR67","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159\u201370.","journal-title":"Leukemia"},{"key":"1286_CR68","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","volume":"95","author":"L Lode","year":"2010","unstructured":"Lode L, Eveillard M, Trichet V, Soussi T, Wuilleme S, Richebourg S, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95:1973\u20136.","journal-title":"Haematologica"},{"key":"1286_CR69","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1158\/1078-0432.CCR-21-3695","volume":"28","author":"P Sudha","year":"2022","unstructured":"Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun MH, et al. Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clin Cancer Res. 2022;28:2854\u201364.","journal-title":"Clin Cancer Res"},{"key":"1286_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.72","volume":"6","author":"N Bolli","year":"2016","unstructured":"Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, et al. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J. 2016;6:e467.","journal-title":"Blood Cancer J"},{"key":"1286_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0062-y","volume":"8","author":"BS White","year":"2018","unstructured":"White BS, Lanc I, O\u2019Neal J, Gupta H, Fulton RS, Schmidt H, et al. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J. 2018;8:35.","journal-title":"Blood Cancer J"},{"key":"1286_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0264-y","volume":"9","author":"V Yellapantula","year":"2019","unstructured":"Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R, et al. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer J. 2019;9:101.","journal-title":"Blood Cancer J"},{"key":"1286_CR73","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1182\/blood.2021014309","volume":"139","author":"YMN Akkari","year":"2022","unstructured":"Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, et al. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022;139:2273\u201384.","journal-title":"Blood"},{"key":"1286_CR74","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s002770000245","volume":"80","author":"A Draube","year":"2001","unstructured":"Draube A, Pfister R, Vockerodt M, Schuster S, Kube D, Diehl V, et al. Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement. Ann Hematol. 2001;80:83\u201389.","journal-title":"Ann Hematol"},{"key":"1286_CR75","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/ajcp\/aqad108","volume":"161","author":"MF Gagnon","year":"2024","unstructured":"Gagnon MF, Midthun SM, Fangel JA, Schuh CM, Luoma IM, Pearce KE, et al. Superior detection rate of plasma cell FISH using FACS-FISH. Am J Clin Pathol. 2024;161:60\u201370.","journal-title":"Am J Clin Pathol"},{"key":"1286_CR76","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1309\/AJCPF7NFLW8UAJEP","volume":"136","author":"L Hartmann","year":"2011","unstructured":"Hartmann L, Biggerstaff JS, Chapman DB, Scott JM, Johnson KR, Ghirardelli KM, et al. Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques. Am J Clin Pathol. 2011;136:712\u201320.","journal-title":"Am J Clin Pathol"},{"key":"1286_CR77","doi-asserted-by":"publisher","first-page":"625","DOI":"10.5858\/arpa.2012-0209-OA","volume":"137","author":"G Lu","year":"2013","unstructured":"Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, et al. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med. 2013;137:625\u201331.","journal-title":"Arch Pathol Lab Med"},{"key":"1286_CR78","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1751-553X.2011.01323.x","volume":"33","author":"G Lu","year":"2011","unstructured":"Lu G, Zhang XX, You MJ, Chen W. Correlation of assessment of plasma cells by flow cytometry and detection of cytogenomic abnormalities by fluorescence in situ hybridization in plasma cell neoplasms. Int J Lab Hematol. 2011;33:545\u201350.","journal-title":"Int J Lab Hematol"},{"key":"1286_CR79","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cancergencyto.2008.11.007","volume":"189","author":"O Pozdnyakova","year":"2009","unstructured":"Pozdnyakova O, Crowley-Larsen P, Zota V, Wang SA, Miron PM. Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment. Cancer Genet Cytogenet. 2009;189:112\u20137.","journal-title":"Cancer Genet Cytogenet"},{"key":"1286_CR80","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cyto.b.21619","volume":"94","author":"PR Tembhare","year":"2018","unstructured":"Tembhare PR, Ghogale S, Tauro W, Badrinath Y, Deshpande N, Kedia S, et al. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. Cytom B Clin Cytom. 2018;94:509\u201319.","journal-title":"Cytom B Clin Cytom"},{"key":"1286_CR81","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/cyto.b.20512","volume":"78","author":"B Paiva","year":"2010","unstructured":"Paiva B, Almeida J, Perez-Andres M, Mateo G, Lopez A, Rasillo A, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytom B Clin Cytom. 2010;78:239\u201352.","journal-title":"Cytom B Clin Cytom"},{"key":"1286_CR82","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/1055-9965.EPI-07-2649","volume":"17","author":"GJ Ahmann","year":"2008","unstructured":"Ahmann GJ, Chng WJ, Henderson KJ, Price-Troska TL, DeGoey RW, Timm MM, et al. Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. Cancer Epidemiol Biomark Prev. 2008;17:666\u201373.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1286_CR83","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cancergencyto.2006.11.015","volume":"174","author":"JH Christensen","year":"2007","unstructured":"Christensen JH, Abildgaard N, Plesner T, Nibe A, Nielsen O, S\u00f8rensen AG, et al. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark. Cancer Genet Cytogenet. 2007;174:89\u201399.","journal-title":"Cancer Genet Cytogenet"},{"key":"1286_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.101054","volume":"26","author":"Y Akkari","year":"2024","unstructured":"Akkari Y, Baughn LB, Kim A, Karaca E, Raca G, Shao L, et al. Section E6.1-6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes. Genet Med. 2024;26:101054.","journal-title":"Genet Med"},{"key":"1286_CR85","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/GIM.0b013e3182227295","volume":"13","author":"JT Mascarello","year":"2011","unstructured":"Mascarello JT, Hirsch B, Kearney HM, Ketterling RP, Olson SB, Quigley DI, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med. 2011;13:667\u201375.","journal-title":"Genet Med"},{"key":"1286_CR86","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/gcc.21982","volume":"51","author":"M Stevens-Kroef","year":"2012","unstructured":"Stevens-Kroef M, Weghuis DO, Croockewit S, Derksen L, Hooijer J, Elidrissi-Zaynoun N, et al. High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma. Genes Chromosomes Cancer. 2012;51:997\u20131006.","journal-title":"Genes Chromosomes Cancer"},{"key":"1286_CR87","doi-asserted-by":"publisher","unstructured":"Yu Y, Shen H, Liu L, Luo P, Wu S, He J, et al. Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma. J Vis Exp. 2022. https:\/\/doi.org\/10.3791\/63083.","DOI":"10.3791\/63083"},{"key":"1286_CR88","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119:2100\u20135.","journal-title":"Blood"},{"key":"1286_CR89","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","volume":"204","author":"JR Sawyer","year":"2011","unstructured":"Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204:3\u201312.","journal-title":"Cancer Genet"},{"key":"1286_CR90","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1182\/bloodadvances.2019001275","volume":"4","author":"PW Mellors","year":"2020","unstructured":"Mellors PW, Binder M, Ketterling RP, Greipp PT, Baughn LB, Peterson JF, et al. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020;4:2236\u201344.","journal-title":"Blood Adv"},{"key":"1286_CR91","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/blood.V66.2.380.380","volume":"66","author":"GW Dewald","year":"1985","unstructured":"Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985;66:380\u201390.","journal-title":"Blood"},{"key":"1286_CR92","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/modpathol.2017.3","volume":"30","author":"AA Carballo-Zarate","year":"2017","unstructured":"Carballo-Zarate AA, Medeiros LJ, Fang LH, Shah JJ, Weber DM, Thomas SK, et al. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Mod Pathol. 2017;30:843\u201353.","journal-title":"Mod Pathol"},{"key":"1286_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101168","volume":"64","author":"SE Clarke","year":"2024","unstructured":"Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024;64:101168.","journal-title":"Blood Rev"},{"key":"1286_CR94","doi-asserted-by":"publisher","first-page":"491-+","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021;27:491-+.","journal-title":"Nat Med"},{"key":"1286_CR95","doi-asserted-by":"publisher","first-page":"6960.","DOI":"10.1038\/s41467-021-26951-z","volume":"12","author":"SM Tirier","year":"2021","unstructured":"Tirier SM, Mallm JP, Steiger S, Poos AM, Awwad MHS, Giesen N. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021;12:6960.","journal-title":"Nat Commun."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01286-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01286-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01286-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:02:22Z","timestamp":1750208542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01286-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01286-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EA reports consultancy AbbVie. RB reports consultancy Adaptive Biotech, BMS, Caribou Biosciences, Genentech, Janssen, Karyopharm, Legend Biotech, Pfizer, Sanofi, SparkCures; Research: Novartis, Pack Health. RF reports consultancy for AbbVie, Adaptive Biotechnologies, AMGEN, AZeneca, Bayer, Binding Site, BMS (Celgene), Millenium Takeda, Jansen, Juno, Kite, Merck, Pfizer, Pharmacyclics, Regeneron, Sanofi; scientific advisory boards for Adaptive Biotechnologies, Caris Life Sciences, Oncotracker; board of directors for Antegene, AZBio; and patents for FISH in myeloma. SK reports consultancy from BMS\/Celgene, Takeda and Janssen and research funding from BMS (Celgene), Takeda, Novartis, AbbVie, Janssen and Amgen. LBB reports consultancy Genentech. The remaining authors have no interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}